Jun 28, 2020
Immutep Completes Recruitment for Part A Of Phase II TACTI-002 Study
Jun 21, 2020
Immutep Receives A$1,437,826 R&D Tax Incentive
May 30, 2020
Immutep Announces Improving Data from the Phase II TACTI-002 Study
Immutep Reports First Results from INSIGHT-004 Study
May 27, 2020
Immutep Receives US$2.4 Million R&D Tax Incentive from French Government
May 25, 2020
Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting
May 06, 2020
Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
Apr 29, 2020
Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting
Apr 28, 2020
Immutep Reports Positive Phase II TACTI-002 Data
Apr 20, 2020
Enrollment completed for the INSIGHT-004 Study
Immutep Quarterly Activities Report
Apr 14, 2020
Immutep Advances Cell Line Development for IMP761
